anti-tumor therapy with macroencapsulated endostatin producer cells抗肿瘤治疗macroencapsulated血管内皮抑制素生产商细胞.pdfVIP

Rodrigues et al. BMC Biotechnology 2010, 10:19 /1472-6750/10/19 RESEARCH ARTICLE Open Access Anti-tumor therapy with macroencapsulated endostatin producer cells 1 2 1 2 1 Danielle B Rodrigues , Roger Chammas , Natália V Malavasi , Patrícia LN da Costa , Rosa M Chura-Chambi , 1 1* Keli N Balduino , Ligia Morganti Abstract Background: Theracyte is a polytetrafluoroethylene membrane macroencapsulation system designed to induce neovascularization at the tissue interface, protecting the cells from host’s immune rejection, thereby circumventing the problem of limited half-life and variation in circulating levels. Endostatin is a potent inhibitor of angiogenesis and tumor growth. Continuous delivery of endostatin improves the efficacy and potency of the antitumoral therapy. The purpose of this study was to determine whether recombinant fibroblasts expressing endostatin encapsulated in Theracyte immunoisolation devices can be used for delivery of this therapeutic protein for treatment of mice bearing B16F10 melanoma and Ehrlich tumors. Results: Mice were inoculated subcutaneously with melanoma (B16F10 cells) or Ehrlich tumor cells at the foot pads. Treatment began when tumor thickness had reached 0.5 mm, by subcutaneous implantation of 107 recombinant encapsulated or non-encapsulated endostatin producer cells. Similar melanoma growth inhibition was obtained for mice treated with encapsulated or non-encapsulated endostatin-expressing cells. The treatment of mice bearing melanoma tumor with encapsulated endostatin-expressing cells was decreased by 50.0%, whereas a decrease of 56.7% in tumor thickness was obtained for mice treated with non-encapsulated cells. Treatment